Sonoma Pharmaceuticals, Inc. SNOA
We take great care to ensure that the data presented and summarized in this overview for Sonoma Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SNOA
View allLatest Institutional Activity in SNOA
Top Purchases
Top Sells
About SNOA
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
Insider Transactions at SNOA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 20
2024
|
Poggetto John Dal Controller |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
Jun 20
2024
|
Jerome J Dvonch Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,586
+38.78%
|
-
|
Jun 20
2024
|
Bruce Thornton Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
53,586
+25.76%
|
-
|
Jun 20
2024
|
Amy Moss Trombly Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,586
+25.87%
|
-
|
Jun 30
2023
|
Bruce Thornton Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+31.57%
|
-
|
Jun 30
2023
|
Amy Moss Trombly Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+31.88%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 176K shares |
---|